Circulating Tumor Cells in Patients with Rectal Cancer
common.study.values.description
“Circulating Tumor Cells in Patients With Rectal Cancer”
Objectives: - To establish the rate of circulating tumor cells (CTC) positivity in patients with locally-advanced rectal cancer (LARC), relative to other stages; - To assess changes in detected CTCs associated with neoadjuvant therapy in patients with LARC; - To correlate CTC counts with neoadjuvant treatment response as an indicator of disease risk.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-no
Procedure - Blood Draws
Healthy Participants: Blood (about 2 tablespoons) drawn at 1 time point. Rectal Cancer Participants: Blood (about 2 tablespoons) drawn 1 time before participant starts treatment. Blood also drawn: Just before tumor surgery 1-8 weeks after surgery, or before chemotherapy begins 1-12 weeks after last dose of chemotherapy year after surgery, OR 1 year after completion of treatment if no surgery years after surgery, OR 2 years after completion of treatment if no surgery If the disease gets worse dur ...read more on ClinicalTrials.org
participant.views.study.view.additional
participant.views.study.view.scientific-title
Circulating Tumor Cells in Patients With Rectal Cancer
common.study.values.clinical-trial-id
NCT02874885
participant.views.study.view.id
RdGxJe
